Ignite Creation Date:
2025-12-25 @ 1:17 AM
Ignite Modification Date:
2026-03-02 @ 3:48 PM
Study NCT ID:
NCT02875093
Status:
TERMINATED
Last Update Posted:
2020-03-05
First Post:
2016-08-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Sponsor:
Polaris Group
Organization:
Study Overview
Official Title:
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia
Status:
TERMINATED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study Termination
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: